Angiocrine Bioscience
John Fraser is currently the Chief Scientific Officer at Angiocrine Bioscience, Inc. Prior to this role, John held various positions at StemSource/Macropore Biosurgery/Cytori Therapeutics over an 18-year period, eventually concluding their tenure as Chief Scientist. John also served as an Adj Associate Professor at the Division of Hematology-Oncology, Dept of Medicine, UCLA School of Medicine, where John was the Director of the UCLA Umbilical Cord Blood Bank. John obtained their PhD in Hematopoietic Stem Cell Biology from the University of Otago and their BSc (hons) in Biochem/Physiol from Victoria University of Wellington.
Angiocrine Bioscience
Angiocrine Bioscience is a private, clinical-stage cell and gene therapy company harnessing the power of genetically modified human endothelial cells to regenerate tissues, restore function and rejuvenate patients with serious medical conditions.